Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...